期刊文献+

新型酪氨酸激酶抑制剂XCF-43b体外抗血管新生研究 被引量:3

Mechanism of In Vitro Anti-Angiogenesis of Tyrosine Kinase Inhibitor XCF-43b
原文传递
导出
摘要 目的探究XCF-43b体外抗血管新生机理。方法鸡胚尿囊膜(CAM)检测化合物抑制血管新生能力.MTY检测其对HUVEC细胞增殖影响,划痕实验和微管形成实验检测化合物对HUVEC迁移和微管形成的影响,Western印迹检测VEGFR2信号通路相关蛋白表达情况。结果XCF-43b能够抑制CAM血管新生,抑制HUVEC细胞增殖的IC50为(28.42±7.23)[zmol/L,对在VEGF刺激下的HUVEC的Ic50值为(9.03±1.28)μmol/L,此外,2.5μmol/L的XCF-43b能够抑制HUVEC细胞的迁移和微管形成;且能够抑制VEGFR2及其下游信号因子的激活。结论XCF-43b通过抑制VEGFR2信号通路来抑制血管新生。 Objective To explore the in vitro anti-angiogenesis mechanism of XCF- 43b. Methods The proliferation of human umbilical vein endothelial cells (HUVEC) was detected by MTF assay and the migration and tube formation of HUVEC were studied by scratches and tube formation. Western blotting was used to detect the expression of VEGFR2 signaling pathway. Results Our results showed that XCF-d3b was able to inhibit angiogenesis by CAM. MTT assay exhibited that XCF-43b could inhibit the proliferation of HUVEC cells. In addition, XCF-43b was found to in- hibit the migration of HUVEC and microtubule formation. Western blot analysis revealed that XCF- 43b was able to inhibit VEGFR2 signaling pathway. Conclusion XCF-43b inhibits angiogenesis by inhibiting VEGFR2 signaling pathway.
出处 《医学分子生物学杂志》 CAS 2017年第3期130-136,共7页 Journal of Medical Molecular Biology
基金 国家自然科学基金(No.U1202221,81560601),云南省自签科学基金(No.2014FD011)
关键词 抗血管新生 VEGFR2 tumor anti-angiogenesis VEGFR2
  • 相关文献

参考文献2

二级参考文献33

  • 1Dawson D W,J Cell Biol,1997年,138卷,3期,707页
  • 2Gnarra J R,Proc Nat Acad Sci USA,1996年,93卷,20期,10589页
  • 3Ilipoulos O,Proc Nat Acad Sci USA,1996年,93卷,20期,10595页
  • 4North S, Moenner M, Bikfalvi A. Recent developments in the regula- tion of the angiogenic switch by cellular stress factors in tumors. Can cer Lett, 2005, 218(1):1-14.
  • 5Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular pat- terning in tumors. J,Cell Biol, 2005, 169(4) :6814~91.
  • 6Anand S, Majeti BK, Acevedo LM, et al. MicroRNA-132-mediated loss of pl20RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med, 2010, 16(8) :909-914.
  • 7Niu G, Chen X. Vascular endothelial growth factor as an anti-angio- genic target for cancer therapy. Curr Drug Targets, 2010, 11 (8): 1000-1017.
  • 8] Yana I, Sagara H, Takaki S, et al. Crosstalk between neovessels and mura ceils directs the site-specific expression of MTI-MMP to endo- thelial tip cells. J Cell Sci, 2007, 120 ( Pt 9) : 1607-1614.
  • 9Weis SM. Evaluating integrin function in models of angiogenesis andvascular permeability. Methods Enzymol, 2007, 426:505-528.
  • 10Del Pozo MA, Schwartz MA. Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. Trends Cell Biol, 2007, 17 (5) :246-250.

共引文献7

同被引文献21

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部